Meeting
2023 ASCO Breakthrough
Identification of intratumoral and peripheral T-cell receptor (TCR) repertoire features associated with acquired (Ar) and primary (Pr) resistance to immune checkpoint inhibitors (ICI).
Authors
Sofia Genta
Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
Sofia Genta , Shirin Soleimani , Xuan Li , Stephanie Pedersen , Alisa Nguyen , Albiruni Ryan Abdul Razak , Samuel Saibil , Marcus O. Butler , Philippe L. Bedard , Tong Zhang , Ming Sound Tsao , Ben X Wang , Nittusha Singaravelan , Andrea Covelli , John R. de Almeida , Aaron Richard Hansen , Lawson Eng , Trevor J. Pugh , Lillian L. Siu , Anna Spreafico
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Gastrointestinal Cancer,Gynecologic Cancer,Head and Neck Cancer,Quality of Care,Genetics/Genomics/Multiomics,Healthcare Equity and Access to Care,Healthtech Innovations,Models of Care and Care Delivery,Population Health,Viral-Mediated Malignancies
Sub Track
Immunotherapies
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 59)
DOI
10.1200/GO.2023.9.Supplement_1.59
Abstract #
59
Poster Bd #
A1
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2022 ASCO Annual Meeting
Assessment of a 4-chemokine signature in prediction of T-cell inflammation and response to immune checkpoint inhibition across tumor types.
First Author: Joan Miguel Romero
Poster
2022 ASCO Genitourinary Cancers Symposium
FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI).
First Author: Elio Adib
Poster
2022 ASCO Genitourinary Cancers Symposium
Bacteria-specific CXCL13-producing follicular helper T cells are putative prognostic markers to neoadjuvant PD-1 blockade in muscle-invasive urothelial carcinoma.
First Author: Anne-Gaëlle Goubet
Poster
2019 ASCO Annual Meeting
Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Updated results.
First Author: Andreas Nicholas Saltos